Genmab A/S released its fourth‑quarter 2025 financial results on February 17, 2026, before the market opened. The company reported revenue of $1.06 billion, a $30 million increase over the consensus estimate of $1.03 billion and a 4 % rise from the $1.02 billion reported in Q3 2025. Earnings per share came in at $0.47, beating the $0.46 consensus estimate by $0.01 and falling short of the $0.65 EPS recorded in the prior quarter.
The results demonstrate a modest revenue gain driven by continued demand for Genmab’s core oncology products, particularly DARZALEX and EPKINLY. The earnings beat, while small, reflects the company’s ability to maintain profitability amid a competitive market and suggests effective cost management. Compared with the prior quarter, EPS declined from $0.65 to $0.47, but the figure still surpassed analyst expectations, underscoring the company’s resilience in a challenging environment.
Genmab’s management highlighted its strategic focus on late‑stage pipeline candidates and the decision to discontinue the acasunlimab program to concentrate resources on higher‑impact opportunities such as EPKINLY, petosemtamab, and Rina‑S. The company’s robust cash position and ongoing pipeline activity provide a foundation for future growth, while the earnings results confirm that its current product mix continues to generate solid revenue and earnings momentum.
No forward guidance was disclosed in the earnings release, leaving investors to interpret the results in the context of Genmab’s recent strategic priorities and the broader oncology market outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.